Twitter

Posts Tagged ‘celgene’


FDA approves Celgene drug for blood cancer

The Food and Drug Administration said Friday it approved a new drug from Celgene for patients with hard-to-treat multiple myeloma, a cancer of the blood.

Read More...

Connect® MDS/AML Disease Registry

Conditions :   Myelodysplastic Syndromes;   Acute Myeloid Leukemia Intervention :   Sponsors :   Celgene Corporation;   Celgene Corporation Not yet recruiting – verified September 2012

Read More...

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Conditions :   B-cell Chronic Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia Interventions :   Drug: lenalidomide;   Other: laboratory biomarker analysis;   Procedure: lymph node biopsy;   Procedure: bone marrow aspiration;   Other: pharmacological study;   Other: flow cytometry Sponsors :   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Celgene Corporation Active, not recruiting – verified July 2012

Read More...

Phase I Study of Lenalidomide in Patients With Acute Leukemia

Condition :   Acute Leukemia Intervention :   Drug: Lenalidomide Sponsors :   University of California, Davis;   University of California, Davis;   Celgene Corporation Not yet recruiting – verified June 2012

Read More...

Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome

Condition :   Myelodysplastic Syndrome (MDS) Intervention :   Drug: Azacitidine Sponsors :   Celgene Corporation;   Celgene Corporation;   PRA International Not yet recruiting – verified May 2012

Read More...

Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma

Condition :   Multiple Myeloma Interventions :   Drug: Lenalidomide;   Drug: Dexamethasone Sponsors :   Celgene Corporation;   Celgene Corporation Active, not recruiting – verified May 2012

Read More...

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma

Condition :   Multiple Myeloma Intervention :   Drug: Pomalidomide Sponsors :   Celgene Corporation;   Celgene Corporation Available – verified April 2012

Read More...

Study Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto)

Conditions :   Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer Interventions :   Drug: nab-Paclitaxel;   Drug: Paclitaxel Sponsors :   German Breast Group;   German Breast Group;   Celgene GmbH;   Roche Pharma AG Not yet recruiting – verified April 2012

Read More...

Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction

Condition :   Acute Myeloid Leukemia Intervention :   Drug: Lenalidomide Sponsors :   UNC Lineberger Comprehensive Cancer Center;   Celgene Corporation Not yet recruiting – verified April 2012

Read More...

Phase I 5-Azacytidine Plus VPA Plus ATRA

Conditions :   Myelodysplastic Syndrome;   Acute Myelogenous Leukemia Interventions :   Drug: 5-Azacytidine (5-aza);   Drug: Valproic Acid;   Drug: All-Trans Retinoic Acid (ATRA) Sponsors :   M.D. Anderson Cancer Center;   Celgene Corporation Completed – verified April 2012

Read More...